Search Results

There are 1059 results for: content related to: ALLERGY Net: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Version of Record online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  3. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

    Allergy

    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Version of Record online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  4. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

    Allergy

    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Version of Record online : 24 APR 2015, DOI: 10.1111/all.12616

  5. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Version of Record online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  6. You have free access to this content
    Effects of omalizumab on markers of inflammation in patients with allergic asthma

    Allergy

    Volume 64, Issue 12, December 2009, Pages: 1728–1736, S. Holgate, N. Smith, M. Massanari and P. Jimenez

    Version of Record online : 15 OCT 2009, DOI: 10.1111/j.1398-9995.2009.02201.x

  7. You have free access to this content
    Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

    Allergy

    Volume 66, Issue 5, May 2011, Pages: 671–678, J. Bousquet, Z. Siergiejko, E. Świebocka, M. Humbert, K. F. Rabe, N. Smith, J. Leo, C. Peckitt, R. Maykut and G. Peachey

    Version of Record online : 21 JAN 2011, DOI: 10.1111/j.1398-9995.2010.02522.x

  8. Integrated Quantitation of Biotherapeutic Drug–Target Binding, Biomarkers, and Clinical Response to Support Rational Dose Regimen Selection

    Standard Article

    Pharmaceutical Sciences Encyclopedia

    Philip J. Lowe, Anne Kümmel, Christina Vasalou, Soichiro Matsushima and Andrej Skerjanec

    Published Online : 30 DEC 2015, DOI: 10.1002/9780470571224.pse548

  9. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x

  10. You have free access to this content
    Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 61–76, Philip J. Lowe, Stacey Tannenbaum, Aurelie Gautier and Pablo Jimenez

    Version of Record online : 26 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03401.x

  11. You have free access to this content
    The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

    Allergy

    Volume 65, Issue 9, September 2010, Pages: 1141–1148, J. D. Campbell, D. E. Spackman and S. D. Sullivan

    Version of Record online : 10 FEB 2010, DOI: 10.1111/j.1398-9995.2010.02336.x

  12. You have free access to this content
    A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab

    British Journal of Clinical Pharmacology

    Volume 63, Issue 5, May 2007, Pages: 548–561, Naoto Hayashi, Yuko Tsukamoto, William M. Sallas and Philip J. Lowe

    Version of Record online : 10 NOV 2006, DOI: 10.1111/j.1365-2125.2006.02803.x

  13. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 701–708, J. G. Ayres, B. Higgins, E. R. Chilvers, G. Ayre, M. Blogg and H. Fox

    Version of Record online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00533.x

  14. You have full text access to this OnlineOpen article
    Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

    Allergy

    A. Magnan, A. Bourdin, C. M. Prazma, F. C. Albers, R. G. Price, S. W. Yancey and H. Ortega

    Version of Record online : 24 MAY 2016, DOI: 10.1111/all.12914

  15. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy

    Allergy

    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Version of Record online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  16. You have free access to this content
    Anti-IgE in severe persistent allergic asthma

    Respirology

    Volume 12, Issue s3, November 2007, Pages: S22–S28, Howard FOX

    Version of Record online : 18 OCT 2007, DOI: 10.1111/j.1440-1843.2007.01016.x

  17. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Version of Record online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  18. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Version of Record online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x

  19. Impact of omalizumab on medical cost of childhood asthma in Japan

    Pediatrics International

    Volume 58, Issue 5, May 2016, Pages: 425–428, Hideki Yoshikawa, Mihoko Iwata, Hiroshi Matsuzaki, Rintaro Ono, Yoko Murakami, Naohiko Taba, Satoshi Honjo, Chikako Motomura and Hiroshi Odajima

    Version of Record online : 13 MAY 2016, DOI: 10.1111/ped.12936

  20. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 8, Issue 12, December 2010, Pages: 990–998, Peter Maximilian Heil, Dieter Maurer, Brigitte Klein, Thomas Hultsch and Georg Stingl

    Version of Record online : 30 JUL 2010, DOI: 10.1111/j.1610-0387.2010.07497.x